Brief: Iveric Bio Announces FDA Accepts New Drug Application And Grants Priority Review For Avacincaptad Pegol For The Treatment Of Geographic Atrophy
16/02/2023 22:55
Feb 16 (Reuters) - IVERIC bio Inc ISEE.O :
* IVERIC BIO ANNOUNCES FDA ACCEPTS NEW DRUG APPLICATION AND
GRANTS
PRIORITY REVIEW FOR AVACINCAPTAD PEGOL FOR THE TREATMENT OF
GEOGRAPHIC ATROPHY
Source text for Eikon: ID:nBw8Bv1dBa
Further company coverage: ISEE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IVERIC bio
See all newsBrief: Astellas Pharma Inc - Astellas Completes Acquisition Of Iveric Bio
Analysis: Amgen's antitrust woes spur wider pharmaceutical deal fears
Iveric Bio Inc Reports Results For The Quarter Ended In March: Earnings Summary
The end of cheap credit could hurry Japanese M&A
U.S. STOCKS ON THE MOVE-US banks, Biomea Fusion, Tutor Perini